We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Promising Treatment Target for Metastatic Breast Cancer Identified

Computer-generated illustration demonstrating targeting of a cancer cell.
Credit: iStock

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Promising Treatment Target for Metastatic Breast Cancer Identified"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

A new University of Kentucky Markey Cancer Center study reveals more about changes that happen to cancer cells when they metastasize and identifies a promising target for the treatment of metastatic breast cancer.

Metastasis is when cancer cells spread from the primary tumor to surrounding tissues and distant organs in the body and is the primary cause for breast cancer mortality. Cancer cells’ plasticity, or their ability to change and adapt, is critical for progression to metastatic cancer.

The research, published in PNAS May 8, shows a metabolite called succinate plays a role in enhancing cancer cell plasticity and identifies an enzyme called PLOD2 as a regulator of succinate during breast cancer progression.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

“The results reveal a previously unidentified function of succinate and its role in breast cancer metastasis, filling a critical gap in our knowledge regarding how changes in metabolites promote cancer cell plasticity,” said Ren Xu, Ph.D., the study’s principal investigator and a professor in the UK College of Medicine’s Department of Pharmacology and Nutritional Sciences.

In collaboration with Andrew N. Lane, Ph.D., professor in the College of Medicine’s Department of Toxicology and Cancer Biology and co-director of the Center for Environmental and Systems Biochemistry, Xu’s team studied metabolic reprogramming in mammary epithelial cells during epithelial mesenchymal transition (EMT), a biologic process that mobilizes cancer cells.

The results also suggest targeting PLOD2 could be a promising strategy to suppress breast cancer metastasis and drug resistance.

PLOD2 expression during EMT elevated succinate levels in breast cancer cells, while PLOD2 inhibition reduced succinate levels and inhibited cancer cell plasticity.

“As PLOD2 is a druggable target, these findings could pave the way for the development of new therapies to stop cancer progression,” said Xu.

Reference: Tong Y, Qi Y, Xiong G, et al. The PLOD2/succinate axis regulates the epithelial–mesenchymal plasticity and cancer cell stemness. PNAS. 2023;120(20):e2214942120. doi: 10.1073/pnas.2214942120

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.